Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT).


Journal Article

Full Text

Duke Authors

Cited Authors

  • Chawla, SP; Blay, J; Ray-Coquard, IL; Le Cesne, A; Staddon, AP; Milhem, MM; Penel, N; Riedel, RF; Bui Nguyen, B; Cranmer, LD; Reichardt, P; Bompas, E; Song, Y; Lee, R; Eid, JE; Loewy, J; Haluska, FG; Dodion, PF; Demetri, GD

Published Date

  • May 20, 2011

Published In

Volume / Issue

  • 29 / 15_suppl

Start / End Page

  • 10005 - 10005

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2011.29.15_suppl.10005


  • en